The bioequivalence study design recommendations for immediate-release solid oral dosage forms in the international pharmaceutical regulators programme participating regulators and organisations: differences and commonalities

• Asıl Yazarlar: Eduardo Agostinho Freitas Fernandes (Yazar), Joy van Oudtshoorn (Yazar), Andrew Tam (Yazar), Liliana Carolina Arévalo González (Yazar), Erwin Guzmán Aurela (Yazar), Henrike Potthast (Yazar), Katalina Mettke (Yazar), Ryosuke Kuribayashi (Yazar), Kohei Shimojo (Yazar), Miho Kasuga (Yazar), Lázaro Morales (Yazar), Zulema Rodríguez (Yazar), Ben Jones (Yazar), Choongyul Ahn (Yazar), Eunju Yun (Yazar), So Hee Kim (Yazar), Clare Rodrigues (Yazar), Toh Tiong (Yazar), Christopher Crane (Yazar), Chantal Walther (Yazar), Matthias S. Roost (Yazar), Tzu-Ling Chen (Yazar), Li-feng Hsu (Yazar), April C. Braddy (Yazar), Alfredo García-Arieta (Yazar), Ivana Abalos (Yazar), Milly Divinsky (Yazar), Abdulaziz Alsuwyeh (Yazar), Bader Alzenaidy (Yazar), Adel Alharf (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Frontiers Media S.A., 2024-03-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Bioequivalence (BE) studies are considered the standard for demonstrating that the performance of a generic drug product in the human body is sufficiently similar to that of its comparator product. The objective of this article is to describe the recommendations from participating Bioequivalence Wor...